MacPherson Edward Clouston 4

What Happened

• Edward Clouston MacPherson, a director of Telomir Pharmaceuticals (TELO), had an exchange of derivative awards on 2026-05-21: a new option/award for 25,000 shares was granted (reported as an acquisition/award) and a prior 25,000-share option was cancelled/returned to the issuer (reported as a disposition). No exercise or open-market sale of common shares occurred. The filing lists no dollar prices or proceeds for these transactions.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-22 (timely).
• Reported items: Grant/acquisition of 25,000 derivative securities and disposition (cancellation) of 25,000 derivative securities. Price: N/A / Proceeds: N/A.
• Footnotes: F1 — the options are fully exercisable. F2 — the reporting person agreed to cancel the option granted 08/27/2024 in exchange for a new option with a lower exercise price (a repricing/exchange).
• Shares owned after transaction: not specified in the provided filing details.

Context

• This was an option exchange/regrant (repricing), not an exercise or sale of shares. Repricings are often done to reset the exercise price on previously granted options; they do not by themselves generate cash proceeds to the insider nor indicate an immediate sale of stock.
• For retail investors: such derivative transactions change the director’s potential future equity stake if options are exercised, but they are not the same as buying or selling shares on the open market and should be weighed alongside other insider activity and company fundamentals.